CLS has entered agreement with Quadia Diagnostic Imaging Center in Piaseczno, Poland on commercial evaluation of TRANBERG® Thermal Therapy System in MR-guided ablation of localized prostate cancer
Clinical Laserthermia Systems AB (publ) today announced that the company has entered an agreement with Quadia Diagnostic Imaging Center in Piaseczno, Poland on a commercial evaluation of its second-generation TRANBERG® Thermal Therapy System with Thermoguide™ Workstation in MR-guided stereotactic focal laser ablation of localized prostate cancer.
“We are very pleased that Quadia, a private imaging center with well-established reputation on the Polish market as the leading site in the MRI diagnostics of prostate cancer and other urological malignancies, have decided to evaluate our second-generation TRANBERG® Thermal Therapy System with Thermoguide™ Workstation in MR-guided stereotactic FLA for minimally-invasive treatment of patients diagnosed with localized prostate cancer”, says Perjan Pleunis, VP Sales in Europe at CLS.
“Today, patients with localized cancer that is confined to the prostate gland are either just observed (Active Surveillance) or receive radical treatment. This may include a surgery, to remove their prostate which exposes them to higher risks of complications such as urinary incontinence or erectile dysfunction. By working with an experienced team of radiologists and urologists and applying our extensive expertise in MR-guided diagnostic procedures to an MR-guided laser focal therapy procedure, we aim at offering our patients with localized prostate cancer a minimally-invasive treatment with faster recovery times and lower risk of complications. We look forward to working with CLS as our partner in developing our therapeutic business”, says Dr. Magdalena Zagrodzka – Radiologist and CEO at Quadia.
CLS second generation TRANBERG® Thermal Therapy System with Thermoguide™ Workstation, for high precision ablation, is CE-marked for installation and integration with MRI scanners from Siemens Healthineers and GE Healthcare and will be showcased this spring at the ECIO meeting in Vienna, Austria during April 24-27.
About localized prostate cancer
About 1,700,000 new cases per year of localized prostate cancer are reported worldwide. Although the landscape of prostate cancer treatment shows several treatment options, there is still an important unmet need for patients who progressed to intermediate risk stage. The currently available surgical options show significant risks and side effects related to urinary and erectile functions and quality of life.
About TRANBERG® | ThermoguideTM Workstation
Thermoguide Workstation connects TRANBERG® | Thermal Therapy System with an MRI scanner and visualizes tissue temperature and extent of tissue ablation performed, both numerically and graphically on the image sequences of the treatment area that are continuously generated by the MRI scanner. By accessing image sequences with minimal delay, the software enables tissue temperature measurements in real time as well as calculation of ablation size with high precision and accuracy. All clearly presented in a graphic user interface to give treating physicians optimal guidance and a safe and efficient workflow during treatment.
Contact information:
Dan J. Mogren, Acting CEO, Clinical Laserthermia Systems AB (publ)
Tel: +46 – (0)705 – 901140 E-mail: dan.mogren@clinicallaser.com
About CLS and TRANBERG
Clinical Laserthermia Systems AB (publ) develops and sells the TRANBERG®|Thermal Therapy Systems, including Thermoguide Workstation and sterile disposables, for minimally invasive treatment of cancer tumors and drug-resistant epilepsy, according to regulatory approvals in the EU and the US. All components of the TRANBERG®|Thermal Therapy Systems have received EU-wide regulatory approval as medical devices (CE-marked class II) for the treatment of soft tissue lesions. CLS is developing its systems to get CE-mark class III for disposable TRANBERG laser applicators to be used in brain as well as expanding the current CE-mark for treatment with imILT®, the Company's interstitial laser thermotherapy for immunostimulatory ablation with potential abscopal effect. CLS is headquartered in Lund and has subsidiaries in Germany, the US and Singapore. CLS is listed on the Nasdaq First North Growth Market under the symbol CLS B. The Certified Advisor (CA) is FNCA Sweden AB, Tel: +46 8 528 00 399. E-mail: info@fnca.se.
For more information about CLS, please visit the Company's website: www.clinicallaser.se
About Quadia
Quadia Sp. z o.o. Sp. K. is a privately-owned diagnostic imaging company providing MRI services specializing in oncology, cardiology and breast imaging. Founded in 2020 by a team of experienced medical doctors, Quadia has a mission to provide high quality medical services by implementing state-of-the-art diagnostic imaging technologies and minimally invasive treatments into daily medical practice. The company currently operates one MRI scanner Siemens Magnetom Sola 1.5T in a clinic in Piaseczno, Poland. The facility is Siemens-Healthineers reference site and participates in multiple clinical research projects.
For more information about Quadia, please visit the Company's website: www.quadia.pl
This disclosure contains information that CLS is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 21-04-2022 08:50 CET.